ArticleLupus science & medicine2026

Fatigue outcomes with anifrolumab in low-disease-activity SLE: DNA damage in plasmacytoid dendritic cells as a candidate biomarker for responders.

Eitaro Yoshida et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.